This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinicaltrials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.
As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinicaltrials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.
XTALKS WEBINAR: All Means All: The Road to Inclusivity in ClinicalTrials. Register for this free webinar to learn what the FDA’s new draft guidance means for diverse and inclusive trials. Register for this free webinar to learn what the FDA’s new draft guidance means for diverse and inclusive trials.
Prior to that, Dr. Zhang was an equity researchanalyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine. ” ABOUT NOVOTECH HEALTH HOLDINGS.
Prior to that, Zhang was an equity researchanalyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. Zhang will be responsible for all aspects of financial management and work closely with Novotech Holdings’ executive team to support the growth of the business across Asia.
To make the most of her first ACRP annual meeting, College plans to attend a variety of sessions that align with her interests and professional goals, such as those scheduled in Content Journeys on regulatory and compliance issues and on clinicaltrial design, among other curated topics.
Nevertheless, this did not stop Trump from tweeting his disapproval of the document saying, “New FDA Rules make it more difficult for them to speed up vaccines for approval before Election Day. Just another political hit job! SteveFDA.”.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content